Redefining HERness: HER2-low and ultralow breast cancers

26 Aug 2024

Jessica LAU

This content is sponsored. It is intended for healthcare professionals only.

The 2018 guidelines from the American Society of Clinical Oncology (ASCO) and the College of American Pathology (CAP) classify human epidermal growth factor receptor-2 (HER2) status in breast cancer (BC) according to immunohistochemistry (IHC) staining results of biopsy specimens, ranging from IHC 0 to IHC 3+, plus in situ hybridization (ISH) test results.1

Redefining-HERness-HER2-low-and-ultralow-breast-cancers

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.